Zeltia Group en el BioSpain 08 . Video presentación de Fernandez Sousa

....una vez presentado el Dossier ante la EMEA del Yondelis en Cancer de Ovario para que esta tome una decisión respecto a la comercialización .... tienen previsto que la decisión de la EMEA sea tomada entre 6 y 10 meses .....

Conclusiones alcanzadas en el Meeting sobre NanoMedecina organizado por el Grupo Zeltia ( Noscira ) .

The meeting concluded with a decision to establish a calendar of short, medium, and long term priorities to be financed and met in order to spur the development of medicines using new technologies. The meeting also featured presentations on three areas in which the EPTN has been focusing: diagnostic technologies, regenerative medicine, and drug delivery systems. Presentations were also given on new advances in the diagnosis and treatment of cancer and neurodegenerative diseases. Jose Maria Fernandez Sousa said: "We need new ways of doing things in the twenty-first century, we need of the interaction of different disciplines and technologies to find new solutions. . . It is the way to achieve the competitiveness we need in Europe." The article can be viewed online at the link below.

Sobre el Meeting :
Noscira , PharmaMar , el Grupo Zeltia y NanoMed organizan del 24 al 26 / 9 en Madrid , el Annual Meeting sobre NanoMedecina .
Programa :
http://etpn.zeltia.com/sites/default/files/ETPN%20110908.pdf

Janssen Pharmaceutica ( J&J ), presents the structure elucidation of four new compounds, formed during the hemisynthetic preparation of trabectedin .